Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
Alexander M.M. Eggermont(University Medical Center Utrecht), Danielle Líénard(University Hospital of Lausanne), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Gerard Groenewegen(University Medical Center Utrecht), Izabella Jagiello(European Organisation for Research and Treatment of Cancer), Cornelis J.A. Punt(Utrecht University), Ulrich Keilholz(German Cancer Research Center), Stefan Suciu(St James's University Hospital), François Salès(Institut Jules Bordet), Dirk J. Ruiter(Radboud University Nijmegen), Rona M. MacKie(University of Glasgow), W. Ruka(Cleveland Clinic), Konstantin Stoitchkov(European Organisation for Research and Treatment of Cancer), Wim H.J. Kruit(Erasmus MC), Michelle Delauney(Hôpital Pellegrin)
Cited by 314
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k